CytomX Therapeutics, Inc.
CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 tā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.57
Price+5.31%
$0.18
1Y
Price
Market Cap
$777.200m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-174.9%
EBITDA Margin-177.9%
Net Profit Margin-249.1%
Free Cash Flow Margin-174.9%
EBITDA Margin-177.9%
Net Profit Margin-249.1%
Free Cash Flow MarginRevenue
$35.542m
-53.4%
1y CAGR-20.6%
3y CAGR+7.2%
5y CAGREarnings
-$59.141m
-240.5%
1y CAGR+1768.6%
3y CAGR+1351.3%
5y CAGREPS
-$0.36
-140.0%
1y CAGR+1206.8%
3y CAGR+930.0%
5y CAGRBook Value
$319.944m
$359.358m
Assets$39.414m
Liabilities$2.856m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$80.194m
-5.8%
1y CAGR-15.2%
3y CAGR+1.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company